Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation
Shepherd J, Jones J, Hartwell D, Davidson P, Price A, Waugh N
Record ID 32007000512
English
Authors' objectives:
"The aim of this systematic review and economic evaluation is to assess the clinical effectiveness and cost-effectiveness of pegylated interferon alfa (PEG) and non-pegylated interferon alfa (IFN) and ribavirin (RBV) for the treatment of adults with histologically mild chronic hepatitis C infection. " (from executive summary)
Authors' recommendations:
The results of this systematic review and economic evaluation show that patients with histologically mild HCV can be successfully treated with both PEG and IFN. Early treatment and watchful waiting strategies are associated with acceptable cost per QALY estimates.
Authors' methods:
Review
Details
Project Status:
Completed
URL for project:
http://www.hta.ac.uk/1472
Year Published:
2007
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Hepatitis C
- Interferon-alpha
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
Copyright:
2009 Queen's Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.